These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

415 related items for PubMed ID: 20459775

  • 1. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma.
    Schnitzbauer AA, Zuelke C, Graeb C, Rochon J, Bilbao I, Burra P, de Jong KP, Duvoux C, Kneteman NM, Adam R, Bechstein WO, Becker T, Beckebaum S, Chazouillères O, Cillo U, Colledan M, Fändrich F, Gugenheim J, Hauss JP, Heise M, Hidalgo E, Jamieson N, Königsrainer A, Lamby PE, Lerut JP, Mäkisalo H, Margreiter R, Mazzaferro V, Mutzbauer I, Otto G, Pageaux GP, Pinna AD, Pirenne J, Rizell M, Rossi G, Rostaing L, Roy A, Turrion VS, Schmidt J, Troisi RI, van Hoek B, Valente U, Wolf P, Wolters H, Mirza DF, Scholz T, Steininger R, Soderdahl G, Strasser SI, Jauch KW, Neuhaus P, Schlitt HJ, Geissler EK.
    BMC Cancer; 2010 May 11; 10():190. PubMed ID: 20459775
    [Abstract] [Full Text] [Related]

  • 2. Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial.
    Geissler EK, Schnitzbauer AA, Zülke C, Lamby PE, Proneth A, Duvoux C, Burra P, Jauch KW, Rentsch M, Ganten TM, Schmidt J, Settmacher U, Heise M, Rossi G, Cillo U, Kneteman N, Adam R, van Hoek B, Bachellier P, Wolf P, Rostaing L, Bechstein WO, Rizell M, Powell J, Hidalgo E, Gugenheim J, Wolters H, Brockmann J, Roy A, Mutzbauer I, Schlitt A, Beckebaum S, Graeb C, Nadalin S, Valente U, Turrión VS, Jamieson N, Scholz T, Colledan M, Fändrich F, Becker T, Söderdahl G, Chazouillères O, Mäkisalo H, Pageaux GP, Steininger R, Soliman T, de Jong KP, Pirenne J, Margreiter R, Pratschke J, Pinna AD, Hauss J, Schreiber S, Strasser S, Klempnauer J, Troisi RI, Bhoori S, Lerut J, Bilbao I, Klein CG, Königsrainer A, Mirza DF, Otto G, Mazzaferro V, Neuhaus P, Schlitt HJ.
    Transplantation; 2016 Jan 11; 100(1):116-25. PubMed ID: 26555945
    [Abstract] [Full Text] [Related]

  • 3. mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors.
    Schnitzbauer AA, Filmann N, Adam R, Bachellier P, Bechstein WO, Becker T, Bhoori S, Bilbao I, Brockmann J, Burra P, Chazoullières O, Cillo U, Colledan M, Duvoux C, Ganten TM, Gugenheim J, Heise M, van Hoek B, Jamieson N, de Jong KP, Klein CG, Klempnauer J, Kneteman N, Lerut J, Mäkisalo H, Mazzaferro V, Mirza DF, Nadalin S, Neuhaus P, Pageaux GP, Pinna AD, Pirenne J, Pratschke J, Powel J, Rentsch M, Rizell M, Rossi G, Rostaing L, Roy A, Scholz T, Settmacher U, Soliman T, Strasser S, Söderdahl G, Troisi RI, Turrión VS, Schlitt HJ, Geissler EK.
    Ann Surg; 2020 Nov 11; 272(5):855-862. PubMed ID: 32889867
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of sirolimus early conversion protocol in liver transplant patients with hepatocellular carcinoma: A single-arm, multicenter, prospective study.
    Su RY, Ling SB, Shan QN, Wei XY, Wang R, Jia CK, Zhuang L, Shen T, Ding LM, Xu ZD, Luo LB, Sun LB, Li GM, Fang TS, Jiang N, Zhang K, Su ZJ, Peng ZH, Lang R, Jiang T, He Q, Ye LS, Yang Y, He YT, Guo WZ, Lan LG, Sun XY, Chen D, Chen ZS, Zhou DW, Ye SJ, Ye QF, Tian M, Shi JH, Wang B, Liu J, Lu Q, Rao W, Cai JZ, Lv T, Yang JY, Wang PS, Zhong L, Ma JS, Li QG, Wu SD, Lu CJ, Lu CD, Zhang DH, Wang X, Li ZQ, Teng MJ, Li JJ, Jiang WT, Li JH, Zhang QB, Zhu NQ, Wang ZX, He K, Xia Q, Song SH, Fu ZR, Qiu W, Lv GY, Song RP, Wang JZ, Wang Z, Zhou J, Chen G, Zhao YP, Li L, Hu ZM, Luo QJ, Si ZZ, Xie B, He XS, Guo ZY, Zheng SS, Xu X.
    Hepatobiliary Pancreat Dis Int; 2022 Apr 11; 21(2):106-112. PubMed ID: 34583911
    [Abstract] [Full Text] [Related]

  • 5. Systematic review with meta-analysis: sirolimus- or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma.
    Grigg SE, Sarri GL, Gow PJ, Yeomans ND.
    Aliment Pharmacol Ther; 2019 May 11; 49(10):1260-1273. PubMed ID: 30989721
    [Abstract] [Full Text] [Related]

  • 6. mTOR inhibitor therapy: Does it prevent HCC recurrence after liver transplantation?
    Duvoux C, Toso C.
    Transplant Rev (Orlando); 2015 Jul 11; 29(3):168-74. PubMed ID: 26071984
    [Abstract] [Full Text] [Related]

  • 7. Sirolimus-based immunosuppression improves the prognosis of liver Transplantation Recipients with low TSC1/2 expression in hepatocellular carcinoma beyond the Milan Criteria.
    Ye Q, Ling S, Jiang G, Shan Q, Xu S, Zhan Q, Wu Y, Liu Y, Zheng S, Xu X.
    Eur J Surg Oncol; 2021 Oct 11; 47(10):2533-2542. PubMed ID: 33902956
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation.
    Gomez-Martin C, Bustamante J, Castroagudin JF, Salcedo M, Garralda E, Testillano M, Herrero I, Matilla A, Sangro B.
    Liver Transpl; 2012 Jan 11; 18(1):45-52. PubMed ID: 21932373
    [Abstract] [Full Text] [Related]

  • 10. Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experience.
    Zhou J, Fan J, Wang Z, Wu ZQ, Qiu SJ, Huang XW, Yu Y, Sun J, Xiao YS, He YF, Wang YQ, Tang ZY.
    World J Gastroenterol; 2006 May 21; 12(19):3114-8. PubMed ID: 16718799
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma.
    Zimmerman MA, Trotter JF, Wachs M, Bak T, Campsen J, Skibba A, Kam I.
    Liver Transpl; 2008 May 21; 14(5):633-8. PubMed ID: 18324656
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Immunosuppressive Treatment With mTOR Inhibitors for Malignancies After Liver Transplantation: Long-Term Survival Retrospective Analysis.
    Tejedor-Tejada J, Alonso-Martín C, Almohalla-Álvarez C, Valenzuela EF, Muñoz RN, Delgado LS, Martín CM, Sánchez-Martín F, García-Pajares F, Sánchez-Antolín G.
    Transplant Proc; 2020 Jun 21; 52(5):1507-1510. PubMed ID: 32213292
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Rescue immunosuppression with mammalian target of rapamycin inhibitor drugs in liver transplantation.
    Mártinez JM, Pulido LB, Bellido CB, Usero DD, Aguilar LT, Moreno JL, Artacho GS, Díez-Canedo JS, Gómez LM, Bravo MA.
    Transplant Proc; 2010 Mar 21; 42(2):641-3. PubMed ID: 20304212
    [Abstract] [Full Text] [Related]

  • 17. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma.
    Kneteman NM, Oberholzer J, Al Saghier M, Meeberg GA, Blitz M, Ma MM, Wong WW, Gutfreund K, Mason AL, Jewell LD, Shapiro AM, Bain VG, Bigam DL.
    Liver Transpl; 2004 Oct 21; 10(10):1301-11. PubMed ID: 15376305
    [Abstract] [Full Text] [Related]

  • 18. Everolimus-based immunosuppression in patients with hepatocellular carcinoma at high risk of recurrence after liver transplantation: a case series.
    Ferreiro AO, Vazquez-Millán MA, López FS, Gutiérrez MG, Diaz SP, Patiño MJ.
    Transplant Proc; 2014 Dec 21; 46(10):3496-501. PubMed ID: 25498079
    [Abstract] [Full Text] [Related]

  • 19. Survival analysis of sirolimus-based immunosuppression in liver transplantation in patients with hepatocellular carcinoma.
    Xu SL, Zhang YC, Wang GY, Yang Q, Liu B, Zhang J, Li H, Wang GS, Yang Y, Chen GH.
    Clin Res Hepatol Gastroenterol; 2016 Dec 21; 40(6):674-681. PubMed ID: 27825633
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.